Algiax Pharmaceuticals Announces Positive Interim Analysis of Phase 2a Study with Lead Candidate AP-325 in Chronic Neuropathic Pain

— Data Monitoring Committee recommends continuation of the study with no safety alerts within the study population 

— Company is ramping up patient recruitment by doubling number of countries and clinical sites

— AP-325 is a small molecule aimed at reducing neuropathic pain by activating GABAA signaling

DÜSSELDORF, GERMANY, May 30, 2023 – Algiax Pharmaceuticals, today provided an update on its ongoing Phase 2a study (NCT04429919) with lead candidate AP-325 in patients with chronic neuropathic pain. As part of a planned mid-enrollment interim analysis, the independent Data Monitoring Committee (DMC) recommended the continuation of the study and confirmed the absence of safety issues among the study participants. Based on the positive DMC review and confirmed financial commitment from its investors, the company will expand the trial to Belgium, France, and Italy. The study is continuing as planned with topline efficacy readouts and a more in-depth safety analysis expected at the conclusion in 2024. AP-325 is a small molecule drug candidate that binds and modulates the GABAreceptor thereby reducing the excitability of the respective neurons. Neuropathic pain is a chronic condition that is oftentimes associated with an imbalance in excitatory and inhibitory neuronal signals. By consistently counteracting the excessive activation of neurons, signaling can be dampened resulting in reduced levels of pain. 

“Over the last decades there has been no innovation in neuropathic pain drug development that has achieved durable patient benefit and the field has been shattered with discontinuations due to lack of efficacy or poor long-term tolerability. With both the preclinical and clinical data we have seen to date for AP-325, we are convinced that we can provide a new treatment to patients that has the potential to achieve long-term benefit,” said Ingo Lehrke, Ph.D., Chief Executive Officer of Algiax Pharmaceuticals. “Together with the committed financial support from our investors, we are well financed and on our way to establishing clinical proof of concept for AP-325.”

“Current treatment of neuropathic pain is dominated by anti-epileptic medicines, antidepressants, and traditional painkillers, none of which provide any long-term pain alleviation. The burden and reduction in quality of life remains high for these patients, with many of them being unable to work and participate in normal day-to-day activities,” said Claudia Sommer, Professor of Neurology at the University of Würzburg, past president of the International Association for the Study of Pain (IASP) and clinical expert in Algiax’s advisory board. “Algiax’s AP-325 has a promising profile with a novel mode of action and already demonstrated a long-lasting reduction of neuropathic pain in preclinical studies. The strong safety profile confirmed in the clinic further validates this approach which is critical in the treatment of a chronic condition. I am looking forward to further exploring its potential with the full Phase 2a analysis in 2024.”

AP-325 is a unique small molecule designed to act as a positive allosteric modulator of the GABAA receptor in the dorsal root ganglion (DRG). The DRG is susceptible to focal treatment with GABAA modulators, allowing AP-325 to restore spinal inhibition and reduce pain. In its preclinical evaluation, Aligax’s lead candidate demonstrated dose-dependent, long-lasting efficacy on mechanical and thermal pain reception in models of central neuropathic pain, peripheral neuropathic pain, and diabetic neuropathy. Furthermore, AP-325 demonstrated a favorable safety profile with no signs of central side effects like drug addiction or dizziness. 

The compound is currently being investigated in a randomized, double-blind, placebo-controlled Phase 2a clinical trial as a monotherapy in patients with peripheral post-surgical neuropathic pain to assess safety and efficacy. The study aims to enroll 96 participants in Germany, Spain, and the Czech Republic with expansion to Italy, Belgium, and France at a total of 27 sites. Enrolment is on schedule and the new clinical trial sites in Belgium, France, and Italy are expected to be initiated shortly. The study’s primary endpoint is to determine the change in the Pain Intensity Numerical Rating Scale (PI-NRS) to evaluate drug efficacy. Secondary endpoints include the longitudinal analysis of the 5-day average PI-NRS score as well as the extent of the response to treatment.

About Algiax

Algiax Pharmaceuticals is dedicated to providing better long-lasting treatment options for neuropathic pain alleviating the burden of this chronic condition by modulating GABAsignaling. Its lead small-molecule candidate AP-325 is currently being investigated in a Phase 2 study and has already demonstrated promising disease modification in preclinical studies as well as a good safety profile in early clinical evaluation. The company aims to further explore the potential of GABAA modulation through its proprietary Thioacrylamide (ThAc) derivatives as follow-up candidates for neuropathic pain.


Algiax Pharmaceuticals GmbH

Ingo Lehrke, CEO

Trophic Communications 

Stephanie May or Alexander Siebert

Phone: +49 171 1855682

Privacy Policy

1. An overview of data protection


The following gives a simple overview of what happens to your personal information when you visit our website. Personal information is any data with which you could be personally identified. Detailed information on the subject of data protection can be found in our privacy policy found below.

Data collection on our website

Who is responsible for the data collection on this website? The data collected on this website are processed by the website operator. The operator’s contact details can be found in the website’s required legal notice. How do we collect your data? Some data are collected when you provide it to us. This could, for example, be data you enter on a contact form. Other data are collected automatically by our IT systems when you visit the website. These data are primarily technical data such as the browser and operating system you are using or when you accessed the page. These data are collected automatically as soon as you enter our website. What do we use your data for? Part of the data is collected to ensure the proper functioning of the website. Other data can be used to analyze how visitors use the site. What rights do you have regarding your data? You always have the right to request information about your stored data, its origin, its recipients, and the purpose of its collection at no charge. You also have the right to request that it be corrected, blocked, or deleted. You can contact us at any time using the address given in the legal notice if you have further questions about the issue of privacy and data protection. You may also, of course, file a complaint with the competent regulatory authorities.

2. General information and mandatory information

Data protection

The operators of this website take the protection of your personal data very seriously. We treat your personal data as confidential and in accordance with the statutory data protection regulations and this privacy policy. If you use this website, various pieces of personal data will be collected. Personal information is any data with which you could be personally identified. This privacy policy explains what information we collect and what we use it for. It also explains how and for what purpose this happens. Please note that data transmitted via the internet (e.g. via email communication) may be subject to security breaches. Complete protection of your data from third-party access is not possible.

Notice concerning the party responsible for this website

The party responsible for processing data on this website is: Dr. Ingo Lehrke Max-Planck-Str. 15a 40699 Erkrath Telephone: +49 (0) 211 617 851 0 Email: The responsible party is the natural or legal person who alone or jointly with others decides on the purposes and means of processing personal data (names, email addresses, etc.).

Revocation of your consent to the processing of your data

Many data processing operations are only possible with your express consent. You may revoke your consent at any time with future effect. An informal email making this request is sufficient. The data processed before we receive your request may still be legally processed.

Right to file complaints with regulatory authorities

If there has been a breach of data protection legislation, the person affected may file a complaint with the competent regulatory authorities. The competent regulatory authority for matters related to data protection legislation is the data protection officer of the German state in which our company is headquartered. A list of data protection officers and their contact details can be found at the following link:

Right to data portability

You have the right to have data which we process based on your consent or in fulfillment of a contract automatically delivered to yourself or to a third party in a standard, machine-readable format. If you require the direct transfer of data to another responsible party, this will only be done to the extent technically feasible.

SSL or TLS encryption

This site uses SSL or TLS encryption for security reasons and for the protection of the transmission of confidential content, such as the inquiries you send to us as the site operator. You can recognize an encrypted connection in your browser’s address line when it changes from “http://” to “https://” and the lock icon is displayed in your browser’s address bar. If SSL or TLS encryption is activated, the data you transfer to us cannot be read by third parties.

Opposition to promotional emails

We hereby expressly prohibit the use of contact data published in the context of website legal notice requirements with regard to sending promotional and informational materials not expressly requested. The website operator reserves the right to take specific legal action if unsolicited advertising material, such as email spam, is received.

3. Data collection on our website


Some of our web pages use cookies. Cookies do not harm your computer and do not contain any viruses. Cookies help make our website more user-friendly, efficient, and secure. Cookies are small text files that are stored on your computer and saved by your browser. Most of the cookies we use are so-called “session cookies.” They are automatically deleted after your visit. Other cookies remain in your device’s memory until you delete them. These cookies make it possible to recognize your browser when you next visit the site. You can configure your browser to inform you about the use of cookies so that you can decide on a case-by-case basis whether to accept or reject a cookie. Alternatively, your browser can be configured to automatically accept cookies under certain conditions or to always reject them, or to automatically delete cookies when closing your browser. Disabling cookies may limit the functionality of this website. Cookies which are necessary to allow electronic communications or to provide certain functions you wish to use (such as the shopping cart) are stored pursuant to Art. 6 paragraph 1, letter f of DSGVO. The website operator has a legitimate interest in the storage of cookies to ensure an optimized service provided free of technical errors. If other cookies (such as those used to analyze your surfing behavior) are also stored, they will be treated separately in this privacy policy.

Server log files

The website provider automatically collects and stores information that your browser automatically transmits to us in “server log files”. These are:
  • Browser type and browser version
  • Operating system used
  • Referrer URL
  • Host name of the accessing computer
  • Time of the server request
  • IP address
These data will not be combined with data from other sources. The basis for data processing is Art. 6 (1) (f) DSGVO, which allows the processing of data to fulfill a contract or for measures preliminary to a contract.

Contact form

Should you send us questions via the contact form, we will collect the data entered on the form, including the contact details you provide, to answer your question and any follow-up questions. We do not share this information without your permission. We will, therefore, process any data you enter onto the contact form only with your consent per Art. 6 (1)(a) DSGVO. You may revoke your consent at any time. An informal email making this request is sufficient. The data processed before we receive your request may still be legally processed. We will retain the data you provide on the contact form until you request its deletion, revoke your consent for its storage, or the purpose for its storage no longer pertains (e.g. after fulfilling your request). Any mandatory statutory provisions, especially those regarding mandatory data retention periods, remain unaffected by this provision.


Use of SalesViewer® technology:

This website uses SalesViewer® technology from SalesViewer® GmbH on the basis of the website operator’s legitimate interests (Section 6 paragraph 1 lit.f GDPR) in order to collect and save data on marketing, market research and optimisation purposes.

In order to do this, a javascript based code, which serves to capture company-related data and according website usage. The data captured using this technology are encrypted in a non-retrievable one-way function (so-called hashing). The data is immediately pseudonymised and is not used to identify website visitors personally

The data stored by Salesviewer will be deleted as soon as they are no longer required for their intended purpose and there are no legal obligations to retain them.

The data recording and storage can be repealed at any time with immediate effect for the future, by clicking on in order to prevent SalesViewer® from recording your data. In this case, an opt-out cookie for this website is saved on your device. If you delete the cookies in the browser, you will need to click on this link again.